Publication Date

2017

Document Type

Thesis

Committee Members

Nancy Bigley (Committee Chair), Barbara Hull (Committee Member), Dawn Wooley (Committee Member)

Degree Name

Master of Science (MS)

Abstract

Herpes simplex virus type 1 (HSV-1) is a highly infective human pathogen which infects a wide range of population in North America and worldwide. HSV-1 infection has two phases, lytic and latent. Recurrence of HSV-1 is a major challenge to clinicians to control the infection especially in immune depleted individuals. Acyclovir (ACV) is an antiviral drug used to treat HSV-1 infection. Low solubility of ACV in water, mutation of viral thymidine kinase, and mutation of viral DNA polymerase are major problems that cause usage limitations of ACV. Myrrh has been used as an analgesic and anti-inflammatory natural product in middle eastern countries for centuries. Recently Myrrh has shown a promising therapeutic action against fungal and parasitic infections. In the current study, low concentrations of Myrrh treatment increased cell survival of HSV-1 infected Vero cells. Prolonged exposure to Myrrh was found to be toxic to viable cells. Myrrh treatment of HSV-1 infected Vero cells was compared with ACV treatment of HSV-1 infected Vero cell. Myrrh treatment increased cell survival of infected Vero cells, similar to the effect of ACV treatment. These results provide evidence that Myrrh exerts antiviral effects against herpes virus infection.

Page Count

56

Department or Program

Microbiology and Immunology

Year Degree Awarded

2017

Creative Commons License

Creative Commons Attribution-Noncommercial-Share Alike 3.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.


Share

COinS